Company profile for Kaleido Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s Microbiome Metabolic Therapies (MMT™) are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advanci...
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s Microbiome Metabolic Therapies (MMT™) are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates to address a variety of diseases and conditions with significant unmet patient needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
65 Hayden Avenue Lexington, MA 02421
Telephone
Telephone
(617) 674-9000
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/kaleido-a-flagship-microbiome-startup-lays-off-staff-cash-runway-shrinking-report

K. LaHucik FIERCEBIOTECH
29 Jan 2022

https://www.globenewswire.com/news-release/2022/01/21/2371028/0/en/Kaleido-Biosciences-to-Present-Updated-Data-of-KB295-In-Ulcerative-Colitis-at-the-2022-Crohn-s-and-Colitis-Congress.html

GLOBENEWSWIRE
21 Jan 2022

https://www.globenewswire.com/news-release/2021/10/05/2308569/0/en/Kaleido-Biosciences-Announces-New-Clinical-and-Preclinical-Data-Supporting-Advancement-of-KB295-to-a-Phase-2-Clinical-Study-in-Mild-to-Moderate-Ulcerative-Colitis.html

GLOBENEWSWIRE
05 Oct 2021

https://www.globenewswire.com/news-release/2021/09/29/2305255/0/en/Kaleido-Biosciences-to-Host-Virtual-R-D-Presentation-to-Discuss-Clinical-Data-and-Pipeline-Advancement-on-October-5-2021.html

GLOBENEWSWIRE
29 Sep 2021
Kaleido warned; FDA not persuaded by 'medical food' claim
Kaleido warned; FDA not persuaded by 'medical food' claim

09 Sep 2021

// Joanne S. Eglovitch RAPS

https://www.raps.org/news-and-articles/news-articles/2021/9/fda-slams-kaleido-for-failing-to-submit-ind-for-co

Joanne S. Eglovitch RAPS
09 Sep 2021

https://www.nutraingredients-usa.com/Article/2021/09/08/Synthetic-glycans-developer-issued-warning-over-failure-to-file-IND-in-COVID-19-trials

Hank Schultz NUTRAINGREDIENTS
08 Sep 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty